It is approved in the United States for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. Here, RET is linked to thyroid gland carcinoma.